Sadeea Abbasi
Gastroenterology · Los Angeles, CANPI 1366713513
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $403,298 of the $556,081 with a category attached, or 72.5%. AbbVie accounts for 63.2% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $234,604, 5.8 times the $40,649 reported in 2019. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 786 payments — averaging $707.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$352K
- Johnson & Johnson$135K
- E.r. Squibb & Sons, L.L.C.$29K
- Lilly USA, LLC$19K
- Celltrion USA Inc.$12K
- Pfizer$6K
- plus $3K from 19 others
What the payments were for
- Consulting fees$16,1523%
- Speaking & faculty fees$403,29873%
- Grants$40,0007%
- Travel & lodging$77,47914%
- Food & beverage$18,7493%
- Education$3320%
- Gifts$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 411 | $351,568 |
| Johnson & Johnson | 135 | $135,359 |
| E.r. Squibb & Sons, L.L.C. | 29 | $28,935 |
| Lilly USA, LLC | 30 | $19,090 |
| Celltrion USA Inc. | 14 | $12,282 |
| Pfizer | 21 | $5,767 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $607 |
| Bristol Myers Squibb | 29 | $516 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $400 |
| Sanofi | 10 | $366 |
| Merck | 13 | $248 |
| Regeneron Healthcare Solutions, Inc. | 8 | $151 |
| Ardelyx, Inc. | 4 | $124 |
| Braintree Laboratories, Inc. | 3 | $111 |
| Intuitive Surgical | 1 | $106 |
| Gilead | 4 | $87 |
| Intercept Pharmaceuticals, Inc. | 4 | $78 |
| Madrigal Pharmaceuticals | 3 | $74 |
| Amgen | 2 | $56 |
| Capsovision, Inc. | 1 | $41 |
| Regeneron | 1 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Shionogi Inc | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$556,081 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 75 | $24,168 |
| LinzessLinaclotide | 29 | $22,215 |
| XifaxanRifaximin | 11 | $21,259 |
| VoqueznaVonoprazan Fumarate | 15 | $11,245 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 11 | $9,181 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 50 | $8,068 |
| MotegrityPrucalopride Succinate | 13 | $7,997 |
| Dexlansoprazole DrDexlansoprazole | 12 | $4,725 |
| Budesonide DrBudesonide | 35 | $3,509 |
| Sucralfate | 25 | $3,092 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 26 | $1,620 |
| Omeprazole | 105 | $1,238 |
| Famotidine | 120 | $1,096 |
| Pantoprazole Sodium | 72 | $981 |
| CholestyramineCholestyramine (With Sugar) | 12 | $384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $351,568 | $22,21529 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $607 | $21,25911 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $26 | $11,24515 claims |
| Braintree Laboratories, Inc.Sutab | $111 | $8,06850 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $400 | $7,99713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Los Angeles
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$1.9M
- Gil MelmedLos Angeles$467K
- Venkataraman MuthusamyLos Angeles$297K
- Caroline HwangLos Angeles$279K
- Adarsh ThakerLos Angeles$241K
- Andres YarurLos Angeles$218K
- Joseph PisegnaLos Angeles$210K
- Steven-Huy HanLos Angeles$194K
- Gina ChoiLos Angeles$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.